ZYTIGA ABIRATERONE 250MG TABLET

Zytiga 250mg Tablet

Zytiga 250mg Tablet is an oral anticancer medicine used for the treatment of advanced prostate cancer. It contains Abiraterone Acetate, which works by lowering the production of androgens (male hormones) that fuel the growth of prostate cancer cells.

Description

• Brand Name: Zytiga

• Generic Name: Abiraterone Acetate

• Strength: 250 mg

• Therapeutic Class: Androgen Biosynthesis Inhibitor (Anti-cancer hormone therapy)

• Route of Administration: Oral

• Manufacturer: Janssen Pharmaceuticals (and generics by other pharma companies)

Indications

Zytiga is prescribed for:

• Metastatic Castration-Resistant Prostate Cancer (mCRPC)

• Metastatic High-Risk Castration-Sensitive Prostate Cancer (mCSPC)

It is usually taken in combination with Prednisone or Prednisolone to reduce side effects and improve treatment effectiveness.

Mechanism of Action

• Abiraterone Acetate is converted into Abiraterone in the body.

• It works by blocking CYP17 enzyme, which is needed for the production of testosterone.

• This results in reduced androgen levels, slowing or stopping prostate cancer cell growth.

Dosage & Administration

• Standard dose: 1000 mg daily (4 × 250 mg tablets) taken once daily.

• Must be taken on an empty stomach: at least 1 hour before or 2 hours after food.

• Always taken with Prednisone/Prednisolone as prescribed.

• Swallow tablets whole with water; do not chew or crush.

Side Effects

Common:

• High blood pressure

• Low potassium levels (hypokalemia)

• Fluid retention, swelling in legs or feet

• Hot flashes

• Diarrhea

• Fatigue

Serious (rare):

• Irregular heartbeat

• Adrenal gland problems

• Liver toxicity (abnormal liver function tests)

Precautions

• Regular monitoring of blood pressure, liver function, and potassium levels is essential.

• Not for use in women (especially pregnant women) or children.

• May increase the risk of heart problems → caution in patients with a history of heart disease.

• Avoid with strong CYP3A4 inducers or inhibitors (drug interactions possible).

Storage

• Store at 20°C – 25°C (room temperature).

• Protect from moisture, heat, and light.

• Keep out of reach of children.

FAQs

Q1. What is Zytiga 250mg Tablet used for?
A: It is used to treat advanced prostate cancer (metastatic castration-resistant or high-risk castration-sensitive).

Q2. Do I need to take Zytiga with food?
A: No, it must be taken on an empty stomach. Food increases drug absorption and may cause side effects.

Q3. Why is Zytiga taken with Prednisone?
A: Prednisone helps reduce side effects like fluid retention, low potassium, and adrenal gland issues caused by Abiraterone.

Q4. Can Zytiga cure prostate cancer?
A: No, it does not cure prostate cancer but helps control disease progression, reduce symptoms, and improve survival.

Q5. How long will I need to take Zytiga?
A: Treatment is usually long-term and continues as long as it is effective and side effects are manageable.

TRUSTED Anti Cancer  MEDICINE PROVIDER – UNNATI PHARMAX

References:-

Official Regulatory Sources

• U.S. FDA – ZYTIGA Full Prescribing Information (2020 Label)
  Comprehensive label includes dosage, hepatic impairment dosing recommendations, and administration guidelines.
  https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202379s031s033lbl.pdf FDA Access Data

• EMA – ZYTIGA EPAR (European Public Assessment Report)
  Official assessment detailing indications, usage, and regulatory evaluation of ZYTIGA in the EU.
  https://www.ema.europa.eu/en/medicines/human/EPAR/zytiga European Medicines Agency (EMA)

• DailyMed (U.S. National Library of Medicine) – Abiraterone Acetate 250 mg Tablets
  FDA-approved label featuring tablet description, usage instructions, warnings, and interactions.
  https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2ac063f0-4177-c90f-27c3-e70e29689255 DailyMed

• Janssen (Manufacturer) – Product Composition & Strength Details
  Manufacturer’s reference for ZYTIGA 250 mg uncoated tablets and 500 mg film-coated tablets with ingredients and packaging info.
  https://www.janssenlabels.com/ca/content/labelling/ZYTIGA/zytiga_cpm.pdf janssenlabels.com

• NCBI/PMC – EMA Review Summary (Clinical Use & Dosing)
  Summary of clinical dosing (1,000 mg daily via four 250 mg tablets), administration instructions, and associated precautions.
  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3780635/